General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0YHUDO
ADC Name
Trastu-AzaNIRII-MMAE
Synonyms
Trastu-AzaNIRII-MMAE
   Click to Show/Hide
Organization
Université Bourgogne Europe.; PSL Research University.; Université de Bourgogne.; Federal Institute for Materials Research and Testing (BAM).; CGFL.; Université Grenoble Alpes.
Drug Status
Investigative
Drug-to-Antibody Ratio
2
Structure
Antibody Name
Trastuzumab
 Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
 Antigen Info 
Payload Name
Monomethyl auristatin E
 Payload Info 
Therapeutic Target
Microtubule (MT)
 Target Info 
Linker Name
azaNIRII-BCN-PEG4-VAC-PAB
 Linker Info 
Conjugate Type
Random conjugation through nucleophilic lysines
ADC-specific functional property(2027 Update)
Binding Affinity
Click To Hide/Show 1 ADC-specific functional property Data
Dissocation Constant (Kd) Binding Target Description Reference
0.429 nM
HER2
Calculated Affinity (KD) toward HER-2 for Each Antibody by BLI
[1]
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
0.1
nM
CVCL_1259
Breast ductal carcinoma
Half Maximal inhibitory Concentration (lC50) 
> 100
nM
CVCL_0031
Invasive breast carcinoma
Half Maximal inhibitory Concentration (lC50) 
> 100
nM
CVCL_0062
Breast adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.1 nM Positive HER2 expression (HER2+++/++)
Method Description
According to Vichai et al., (31) experiments were performed in 96-well plates (flat bottom, transparent plate, with lid; Corning-Falcon cat. n° 353072) using a CLARIOstar Plus plate-reader device (BMG LABTECH). Cells were seeded in a 96-well plate at a density of 2 × 103 cells in 100 uL per well, keeping a column of the plate without cells (background control), and allowed to recover for 24 h. Cells were treated live with 100 uL of various concentrations (final concentrations ranging from 0.003 to 100 nM) of trastuzumab conjugates (diluted in supplemented RPMI for HCC1954 and MDA-MB-231 cell lines and in DMEM for MCF7 cell line) or not (negative control = untreated cells; only supplemented with 100 uL of RPMI for HCC1954 and MDA-MB-231 cell lines or with 100 uL of DMEM for MCF7 cell line) in technical triplicates. Cells were incubated for 96 h at 37 °C and 5% CO2 under a humid atmosphere in an IncuCyteS3 (from Sartorius). Cells were fixed with an addition of 100 uL of cold 10% (w/v) trichloroacetic acid (TCA) to wells for 1 h at 4 °C, washed with tap water (×3), allowed to dry overnight at 25 °C, stained with 0.057% (w/v) SRB (in 1% (v/v) acetic acid) for 30 min at 25 °C, then quickly washed with 1% (v/v) acetic acid (×3) and allowed to dry overnight at 25 °C. After incubating the plate with 100 uL of cold 10 mM unbuffered Trizma base solution for 5 min at 25 °C under agitation, the Abs 530 nm was recorded. Final data were analyzed with Excel (Microsoft Corp.) and GraphPad Prism version 10.1.2 for Windows (GraphPad Software, Boston, Massachusetts USA). Mean Abs values and Normalized % cell viability (see below) were calculated. IC50 was calculated in performing a sigmoidal fit ([inhibitor] vs response-variable slope, GraphPad Prism v10.0.0). A minimum of three independent experiments (n = 3) was used. Normalized % cell viability [x] = [ (Mean Abs 530 nm conjugates [x] - Mean Abs 530 nm background control)/ (Mean Abs 530 nm negative control - Mean Abs 530 nm background control)] × 100; with [x] corresponding to the final conjugate's concentration.

   Click to Show/Hide
In Vitro Model Breast ductal carcinoma HCC1954 cells CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 100 nM Negative HER2 expression (HER2-)
Method Description
According to Vichai et al., (31) experiments were performed in 96-well plates (flat bottom, transparent plate, with lid; Corning-Falcon cat. n° 353072) using a CLARIOstar Plus plate-reader device (BMG LABTECH). Cells were seeded in a 96-well plate at a density of 2 × 103 cells in 100 uL per well, keeping a column of the plate without cells (background control), and allowed to recover for 24 h. Cells were treated live with 100 uL of various concentrations (final concentrations ranging from 0.003 to 100 nM) of trastuzumab conjugates (diluted in supplemented RPMI for HCC1954 and MDA-MB-231 cell lines and in DMEM for MCF7 cell line) or not (negative control = untreated cells; only supplemented with 100 uL of RPMI for HCC1954 and MDA-MB-231 cell lines or with 100 uL of DMEM for MCF7 cell line) in technical triplicates. Cells were incubated for 96 h at 37 °C and 5% CO2 under a humid atmosphere in an IncuCyteS3 (from Sartorius). Cells were fixed with an addition of 100 uL of cold 10% (w/v) trichloroacetic acid (TCA) to wells for 1 h at 4 °C, washed with tap water (×3), allowed to dry overnight at 25 °C, stained with 0.057% (w/v) SRB (in 1% (v/v) acetic acid) for 30 min at 25 °C, then quickly washed with 1% (v/v) acetic acid (×3) and allowed to dry overnight at 25 °C. After incubating the plate with 100 uL of cold 10 mM unbuffered Trizma base solution for 5 min at 25 °C under agitation, the Abs 530 nm was recorded. Final data were analyzed with Excel (Microsoft Corp.) and GraphPad Prism version 10.1.2 for Windows (GraphPad Software, Boston, Massachusetts USA). Mean Abs values and Normalized % cell viability (see below) were calculated. IC50 was calculated in performing a sigmoidal fit ([inhibitor] vs response-variable slope, GraphPad Prism v10.0.0). A minimum of three independent experiments (n = 3) was used. Normalized % cell viability [x] = [ (Mean Abs 530 nm conjugates [x] - Mean Abs 530 nm background control)/ (Mean Abs 530 nm negative control - Mean Abs 530 nm background control)] × 100; with [x] corresponding to the final conjugate's concentration.

   Click to Show/Hide
In Vitro Model Invasive breast carcinoma MCF-7 cells CVCL_0031
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 100 nM Negative HER2 expression (HER2-)
Method Description
According to Vichai et al., (31) experiments were performed in 96-well plates (flat bottom, transparent plate, with lid; Corning-Falcon cat. n° 353072) using a CLARIOstar Plus plate-reader device (BMG LABTECH). Cells were seeded in a 96-well plate at a density of 2 × 103 cells in 100 uL per well, keeping a column of the plate without cells (background control), and allowed to recover for 24 h. Cells were treated live with 100 uL of various concentrations (final concentrations ranging from 0.003 to 100 nM) of trastuzumab conjugates (diluted in supplemented RPMI for HCC1954 and MDA-MB-231 cell lines and in DMEM for MCF7 cell line) or not (negative control = untreated cells; only supplemented with 100 uL of RPMI for HCC1954 and MDA-MB-231 cell lines or with 100 uL of DMEM for MCF7 cell line) in technical triplicates. Cells were incubated for 96 h at 37 °C and 5% CO2 under a humid atmosphere in an IncuCyteS3 (from Sartorius). Cells were fixed with an addition of 100 uL of cold 10% (w/v) trichloroacetic acid (TCA) to wells for 1 h at 4 °C, washed with tap water (×3), allowed to dry overnight at 25 °C, stained with 0.057% (w/v) SRB (in 1% (v/v) acetic acid) for 30 min at 25 °C, then quickly washed with 1% (v/v) acetic acid (×3) and allowed to dry overnight at 25 °C. After incubating the plate with 100 uL of cold 10 mM unbuffered Trizma base solution for 5 min at 25 °C under agitation, the Abs 530 nm was recorded. Final data were analyzed with Excel (Microsoft Corp.) and GraphPad Prism version 10.1.2 for Windows (GraphPad Software, Boston, Massachusetts USA). Mean Abs values and Normalized % cell viability (see below) were calculated. IC50 was calculated in performing a sigmoidal fit ([inhibitor] vs response-variable slope, GraphPad Prism v10.0.0). A minimum of three independent experiments (n = 3) was used. Normalized % cell viability [x] = [ (Mean Abs 530 nm conjugates [x] - Mean Abs 530 nm background control)/ (Mean Abs 530 nm negative control - Mean Abs 530 nm background control)] × 100; with [x] corresponding to the final conjugate's concentration.

   Click to Show/Hide
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells CVCL_0062
References
Ref 1 NIR-II aza-BODIPY Platform for the Development of a Fluorescent Antibody Drug Conjugate